Management of the Metabolic Effects of HIV and HIV Drugs

Overview

Journal Nat Rev Endocrinol

Specialty Endocrinology

Date 2011 Sep 21

PMID 21931374

Citations 36

Authors

Todd T Brown

Marshall J Glesby

Affiliations

Soon will be listed here.

Abstract

Morphologic and metabolic abnormalities, including subcutaneous adipose tissue wasting, central adipose tissue accumulation, dyslipidemia and disorders of glucose metabolism are common among HIV-infected patients receiving highly active antiretroviral therapy (HAART) and contribute to the risk of cardiovascular disease in this population. The pathogenesis of these disorders is due to complicated interactions between effects of chronic HIV infection, HAART medications and patient factors, including genetic susceptibility. HAART has transformed HIV into a chronic condition for many patients and as a result the majority of HIV-infected patients in many areas of the developed world will soon be aged ≥50 years. Given that metabolic and cardiovascular diseases increase with aging, knowledge of the optimal management of these conditions is essential for practitioners caring for HIV-infected patients, including endocrine subspecialists. This Review highlights the clinical management of these disorders, focusing on the latest evidence regarding the efficacy of treatment strategies, newly available medications and potential interactions between HAART medications and medications used to treat metabolic disorders.

Citing Articles

Fasting plasma glucose trends in the elderly living with HIV/AIDS on combination antiretroviral therapy regimens.

Shang M, Zhang J, Chen M, Chen X, Liu C, Zhong H BMJ Open. 2024; 14(11):e085266.

PMID: 39496366 PMC: 11535695. DOI: 10.1136/bmjopen-2024-085266.

Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies.

Jain A, Lai V Diabetes Ther. 2024; 15(9):2001-2025.

PMID: 39085746 PMC: 11330434. DOI: 10.1007/s13300-024-01628-0.

Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy.

Virseda-Berdices A, Martin-Escolano R, Berenguer J, Gonzalez-Garcia J, Brochado-Kith O, Rojo D Front Cell Infect Microbiol. 2024; 14:1340610.

PMID: 38550617 PMC: 10972849. DOI: 10.3389/fcimb.2024.1340610.

LGBTQ+ cardiovascular health equity: a brief review.

Bonomo J, Luo K, Ramallo J Front Cardiovasc Med. 2024; 11:1350603.

PMID: 38510198 PMC: 10951381. DOI: 10.3389/fcvm.2024.1350603.

Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection.

Wang Z, Peters B, Bryant M, Hanna D, Schwartz T, Wang T Microbiome. 2023; 11(1):119.

PMID: 37237391 PMC: 10224225. DOI: 10.1186/s40168-023-01566-2.

References

Drechsler H, Powderly W . Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002; 35(10):1219-30. DOI: 10.1086/343050. View

Brown T, Qaqish R . Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165-74. DOI: 10.1097/QAD.0b013e32801022eb. View

Brown T, Li X, Cole S, Kingsley L, Palella F, Riddler S . Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005; 19(13):1375-83. DOI: 10.1097/01.aids.0000181011.62385.91. View

Arioglu Oral E, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P . Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346(8):570-8. DOI: 10.1056/NEJMoa012437. View

Mallon P, Miller J, Kovacic J, Kent-Hughes J, Norris R, Samaras K . Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. AIDS. 2006; 20(7):1003-10. DOI: 10.1097/01.aids.0000222072.37749.5a. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Guaraldi G, Fontdevila J, Christensen L, Orlando G, Stentarelli C, Carli F . Surgical correction of HIV-associated facial lipoatrophy. AIDS. 2010; 25(1):1-12. DOI: 10.1097/QAD.0b013e32833f1463. View

Lennox J, DeJesus E, Berger D, Lazzarin A, Pollard R, Madruga J . Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010; 55(1):39-48. PMC: 6065510. DOI: 10.1097/QAI.0b013e3181da1287. View

Brown T, Tassiopoulos K, Bosch R, Shikuma C, McComsey G . Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010; 33(10):2244-9. PMC: 2945167. DOI: 10.2337/dc10-0633. View

10.

Torriani M, Hadigan C, Jensen M, Grinspoon S . Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol (1985). 2003; 95(3):1005-10. DOI: 10.1152/japplphysiol.00366.2003. View

11.

Diop M, Bastard J, Meunier N, Thevenet S, Maachi M, Capeau J . Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res Hum Retroviruses. 2007; 22(12):1242-7. PMC: 3893615. DOI: 10.1089/aid.2006.22.1242. View

12.

Eron J, Young B, Cooper D, Youle M, DeJesus E, Andrade-Villanueva J . Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010; 375(9712):396-407. DOI: 10.1016/S0140-6736(09)62041-9. View

13.

Vigouroux C, Maachi M, Nguyen T, Coussieu C, Gharakhanian S, Funahashi T . Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003; 17(10):1503-11. DOI: 10.1097/00002030-200307040-00011. View

14.

Martin A, Smith D, Carr A, Ringland C, Amin J, Emery S . Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004; 18(7):1029-36. DOI: 10.1097/00002030-200404300-00011. View

15.

Carr A, Samaras K, Chisholm D, Cooper D . Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998; 351(9119):1881-3. DOI: 10.1016/S0140-6736(98)03391-1. View

16.

Santos C, Felipe Y, Braga P, Ramos D, Lima R, Segurado A . Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS. 2005; 19 Suppl 4:S14-21. DOI: 10.1097/01.aids.0000191485.92285.c7. View

17.

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

18.

McComsey G, Ward D, Hessenthaler S, Sension M, Shalit P, Lonergan J . Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2003; 38(2):263-70. DOI: 10.1086/380790. View

19.

Gerber J, Rosenkranz S, Fichtenbaum C, Vega J, Yang A, Alston B . Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005; 39(3):307-12. DOI: 10.1097/01.qai.0000167156.44980.33. View

20.

Haubrich R, Riddler S, DiRienzo A, Komarow L, Powderly W, Klingman K . Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009; 23(9):1109-18. PMC: 2739977. DOI: 10.1097/QAD.0b013e32832b4377. View